Javascript must be enabled to continue!
MON-345 Hypercalcemia After Placement of Antibiotic-Loaded Calcium Sulfate Beads
View through CrossRef
Abstract
Calcium sulfate beads are used to fill bone voids in bone loss and nonunion, as well as in the management of bone and joint infections.1 Specifically, Stimulan® is an absorbed form of antibiotic-loaded calcium sulfate beads which delivers high local antibiotic concentrations for treatment of infection, but has also been associated with hypercalcemia in 5.4% of cases.1 Despite the significant morbidity associated with hypercalcemia, there is little published literature describing this important complication.
In our institution, five patients hospitalized between March 2019 and September 2019 with normal baseline calcium levels developed hypercalcemia as a complication of Stimulan® placement. Typically, 10 to 60 cc of Stimulan® were inserted in each surgery, with the exception of 120cc in one surgery. Three patients required a second surgery with antibiotic bead placement, and hypercalcemia occurred with both initial and subsequent surgeries. The onset of hypercalcemia varied from post-operative day one to four. The peak corrected calcium was 10.7-16.1 mg/dL which corresponded to ionized calcium of 1.57 to >2.20 mmol/L (normal 1.09-1.29 mmol/L). The patient with the highest bead volume had the highest calcium. Calcium peaked on post-operative days three to five. Patients were treated with intravenous fluids, furosemide, calcitonin and anti-resorptives including denosumab and zoledronic acid. Four patients required hemodialysis. Three patients required dialysis for symptomatic hypercalcemia and in one patient the indication was multifactorial. Calcium typically normalized by post-operative day 14 to 21, but hypercalcemia duration was unknown in two patients (one died; one had hypercalcemia on hospital discharge).
As illustrated in our cases, patients who develop hypercalcemia after their initial antibiotic bead placement may be at risk for recurrent hypercalcemia if additional surgeries use antibiotic beads. Higher bead volume may be associated with more significant hypercalcemia.1 Although previous cases have reported milder hypercalcemia, our cases demonstrate that hypercalcemia can be more severe and prolonged, necessitating dialysis in addition to traditional therapies. 1-3
References:
1.Kallala R, Harris WE, Ibrahim M, Dipane M, McPherson E. Use of Stimulan absorbable calcium sulphate beads in revision lower limb arthroplasty: Safety profile and complication rates. Bone Joint Res. 2018 Nov 3;7(10):570-579.
2.Kallala R, Haddad FS. Hypercalcaemia following the use of antibiotic-eluting absorbable calcium sulphate beads in revision arthroplasty for infection. Bone Joint J. 2015 Sep;97-B(9):1237-41.
3.Carlson Jr. CR, Markulis E, Thompson E, Havill J. A novel case of hypercalcemia following the use of calcium sulfate beads. Nephrol Open J. 2015; 1(1): 17-19.
The Endocrine Society
Title: MON-345 Hypercalcemia After Placement of Antibiotic-Loaded Calcium Sulfate Beads
Description:
Abstract
Calcium sulfate beads are used to fill bone voids in bone loss and nonunion, as well as in the management of bone and joint infections.
1 Specifically, Stimulan® is an absorbed form of antibiotic-loaded calcium sulfate beads which delivers high local antibiotic concentrations for treatment of infection, but has also been associated with hypercalcemia in 5.
4% of cases.
1 Despite the significant morbidity associated with hypercalcemia, there is little published literature describing this important complication.
In our institution, five patients hospitalized between March 2019 and September 2019 with normal baseline calcium levels developed hypercalcemia as a complication of Stimulan® placement.
Typically, 10 to 60 cc of Stimulan® were inserted in each surgery, with the exception of 120cc in one surgery.
Three patients required a second surgery with antibiotic bead placement, and hypercalcemia occurred with both initial and subsequent surgeries.
The onset of hypercalcemia varied from post-operative day one to four.
The peak corrected calcium was 10.
7-16.
1 mg/dL which corresponded to ionized calcium of 1.
57 to >2.
20 mmol/L (normal 1.
09-1.
29 mmol/L).
The patient with the highest bead volume had the highest calcium.
Calcium peaked on post-operative days three to five.
Patients were treated with intravenous fluids, furosemide, calcitonin and anti-resorptives including denosumab and zoledronic acid.
Four patients required hemodialysis.
Three patients required dialysis for symptomatic hypercalcemia and in one patient the indication was multifactorial.
Calcium typically normalized by post-operative day 14 to 21, but hypercalcemia duration was unknown in two patients (one died; one had hypercalcemia on hospital discharge).
As illustrated in our cases, patients who develop hypercalcemia after their initial antibiotic bead placement may be at risk for recurrent hypercalcemia if additional surgeries use antibiotic beads.
Higher bead volume may be associated with more significant hypercalcemia.
1 Although previous cases have reported milder hypercalcemia, our cases demonstrate that hypercalcemia can be more severe and prolonged, necessitating dialysis in addition to traditional therapies.
1-3
References:
1.
Kallala R, Harris WE, Ibrahim M, Dipane M, McPherson E.
Use of Stimulan absorbable calcium sulphate beads in revision lower limb arthroplasty: Safety profile and complication rates.
Bone Joint Res.
2018 Nov 3;7(10):570-579.
2.
Kallala R, Haddad FS.
Hypercalcaemia following the use of antibiotic-eluting absorbable calcium sulphate beads in revision arthroplasty for infection.
Bone Joint J.
2015 Sep;97-B(9):1237-41.
3.
Carlson Jr.
CR, Markulis E, Thompson E, Havill J.
A novel case of hypercalcemia following the use of calcium sulfate beads.
Nephrol Open J.
2015; 1(1): 17-19.
Related Results
Hypercalcemia Etiologies in Pediatric Patients: An Informative Narrative Review
Hypercalcemia Etiologies in Pediatric Patients: An Informative Narrative Review
Background: Hypercalcemia, although less prevalent, is a critical diagnosis in pediatric patients, consisting of numerous etiologies that differ significantly from those in adults....
Procedure for Latex beads coating with glycolipids v1
Procedure for Latex beads coating with glycolipids v1
Goal: This document aims to standardize the protocol for latex beads coating with the Mycobacterium leprae phenolic glycolipid “PGL I”. Beads-PGL I coating is used, for example, fo...
Patient With IgG Heavy Chain Disease Presents With Parathyroid Hormone-Related Peptide Mediated Hypercalcemia
Patient With IgG Heavy Chain Disease Presents With Parathyroid Hormone-Related Peptide Mediated Hypercalcemia
Abstract
Background
Multiple myeloma is associated with excessive tumor-induced, osteoclast-mediated bone destruction. Hypercalc...
Comparative Analysis of Adjusted Calcium and Free Ionized Calcium in Patients with Calcium Derangement in Clinical Setting
Comparative Analysis of Adjusted Calcium and Free Ionized Calcium in Patients with Calcium Derangement in Clinical Setting
Background: Calcium derangements, including hypocalcaemia and hypercalcemia, are significant clinical conditions that affect multiple physiological processes. While adjusted calciu...
MON-LB69 Calcitriol-Mediated Hypercalcemia in a Patient With Metastatic Gastrointestinal Stromal Tumor
MON-LB69 Calcitriol-Mediated Hypercalcemia in a Patient With Metastatic Gastrointestinal Stromal Tumor
Abstract
Background: Hypercalcemia is a common complication of advanced malignancy, affecting up to 30% of cancer patients through various mechanisms (1). Hypercalce...
MON-158 Primary Hyperparathyroidism in Pregnancy: Parathyroidectomy in the Third Trimester
MON-158 Primary Hyperparathyroidism in Pregnancy: Parathyroidectomy in the Third Trimester
Abstract
Disclosure: M.P. Acharya: None. S. Sapna: None. B. Cunningham: None. I. Gabriely: None. A. Gabriely: None.
Primary hyperparathyroidism ...
PSAT225 Severe Hypercalcemia Following Denosumab Withdrawal in Giant Cell Tumor of Bone: A Double-edged Sword Treatment Paradigm?
PSAT225 Severe Hypercalcemia Following Denosumab Withdrawal in Giant Cell Tumor of Bone: A Double-edged Sword Treatment Paradigm?
Abstract
Introduction
Denosumab inhibits receptor activator of nuclear factor k-B ligand and is approved to treat giant cell tum...
Assessment of the Safety of Genetically Modified Soybean Used as MON 87705 X MON 87708 X MON 89788 for Food and Feed Uses Under Assimilated Regulation (EC) No. 1829/2003 (RP2149)
Assessment of the Safety of Genetically Modified Soybean Used as MON 87705 X MON 87708 X MON 89788 for Food and Feed Uses Under Assimilated Regulation (EC) No. 1829/2003 (RP2149)
The Food Standards Agency (FSA) and Food Standards Scotland (FSS) received an application from Bayer CropScience Ltd (“the applicant”) under assimilated Regulation (EC) No. 1829/20...

